Home › Trial NCT03502330
APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
- Trial IDNCT03502330
- StatusCompleted
- PhasePhase 1
- Study typeInterventional
- SponsorYale University
- Enrollment42
- Start date2018-06-09
- ConditionsAdvanced Melanoma · Non-small Cell Lung Cancer · Renal Cell Carcinoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.